Understanding Participation in Renal Cell Carcinoma Studies
This study is looking at why people with renal cell carcinoma (kidney cancer) choose to join other clinical trials that test new treatments. It also tracks how many people stay in those trials until the end and how many leave early. You can join if you are at least 18 years old, have kidney cancer, and are planning to enroll in a separate clinical study. The goal is to understand trends in trial participation. By joining, you would help researchers learn more about how people engage with clinical research, which can improve future studies for kidney cancer patients. This study is not testing a new treatment itself, but rather observing participation in other treatment studies.
- Study design
- This is an observational study aiming to enroll 500 participants. It is not testing a specific drug or intervention.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study measures participation at 3 months and trial completion rates at 12 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Delving Into Participation Trends in Renal Cell Carcinoma Studies
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Michael B Gill · STUDY_DIRECTOR · Power Life Sciences Inc.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Number of patients who decide to participate in a renal cell carcinoma clinical study3 months
- Rate of patients who remain in renal cell carcinoma clinical trial to trial completion12 months